Mistletoe cancer therapy is an innovative complementary treatment gaining recognition worldwide for its supportive role in oncology. ABNOBA GmbH, a research-driven pharmaceutical company based in Pforzheim, Germany, has pioneered the development of high-quality mistletoe extracts. Through its branch ABNOBA India, the company is introducing this integrative therapy to the Indian healthcare landscape.
Unlike conventional treatments that directly target cancer cells, mistletoe therapy focuses on strengthening the body’s natural defenses. Extracts from the European mistletoe plant (Viscum album) are administered through injections, stimulating the immune system and enhancing the patient's ability to cope with the disease and its treatment. It is particularly effective in improving quality of life, reducing fatigue, and managing side effects associated with chemotherapy and radiation.
ABNOBA’s mistletoe products are supported by decades of clinical research and manufactured under strict pharmaceutical standards. Each preparation is designed to match the patient’s condition and stage of treatment, ensuring personalized and effective care.
In India, where integrative medicine is widely accepted, ABNOBA India is bridging the gap between modern science and natural therapies. Through awareness programs and medical education, they are empowering doctors and patients to explore holistic options alongside standard oncology protocols.
Mistletoe therapy is not a cure, but it is a powerful ally in the fight against cancer. To learn more about this complementary approach, visit www.abnoba.in and discover how nature and science come together for better cancer care.
